Table 4.
ONO‐4474 | Placebo | |
---|---|---|
Adverse Event | (n = 55) | (n = 55) |
Total TEAEs, n (%) | 23 (41.8) | 10 (18.2) |
Serious TEAEs, n (%) | – | 1 (1.8) |
Discontinued treatment due to TEAEs, n (%) | 4 (7.3) | 1 (1.8) |
Total ADRs, n (%) | 16 (29.1) | 7 (12.7) |
Serious ADRs, n (%) | – | – |
Discontinued treatment due to ADRs, n (%) | 3 (5.5) | 1 (1.8) |
ADR, adverse drug reaction; TEAE, treatment‐emergent adverse event.